ACE-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ACE2 (UniProt Q9BYF1), expressed in HEK293 cells. Suited for carboxypeptidase activity assays, spike-protein binding studies, inhibitor screening, and antibody validation controls.
Expression system
HEK293
Cat. #
REC-ACE2

In stock

SKU
REC-ACE2
$498.00

Target Overview

ACE-2 (Angiotensin-Converting Enzyme 2; UniProt Q9BYF1) is a type I transmembrane zinc metallocarboxypeptidase encoded by the ACE2 gene. The full-length human protein spans 805 amino acids; the catalytically active ectodomain (approximately residues 18–740) is the form most commonly employed in biochemical and binding studies. This recombinant is produced in HEK293 mammalian cells, which provide the glycosylation pattern and tertiary folding characteristic of the native human enzyme — features relevant to both carboxypeptidase activity and receptor-binding experiments where post-translational modifications influence interaction fidelity. ACE2 functions as the primary counter-regulatory arm of the renin-angiotensin system (RAS), converting angiotensin II to the vasodilatory heptapeptide angiotensin 1-7, and angiotensin I to angiotensin 1-9. Beyond RAS substrates, the enzyme cleaves apelins (apelin-13, apelin-17, apelin-36), casomorphins, and dynorphin A with measurable efficiency, making it a useful tool for broad peptide-substrate profiling experiments. In vitro, researchers use this recombinant to measure carboxypeptidase kinetics against fluorogenic or peptide substrates, to screen small-molecule and peptide inhibitors by IC50 determination, and to quantify binding affinity of viral spike proteins — most notably the SARS-CoV-2 receptor-binding domain — by SPR, BLI, or ELISA-format assays. The HEK293 expression system is widely used for ACE2 in binding assays where glycan-dependent contacts with the spike RBD are under investigation. Researchers validating anti-ACE2 antibodies can use this recombinant as a positive control antigen. It pairs directly with the Triple Point Biologics matched antibody (SKU: RP-ACE2), which has been validated for Western blot against human ACE2.

Background

ACE2 was originally characterised as a homolog of somatic ACE (angiotensin-converting enzyme) with a distinct monocarboxypeptidase activity, cleaving a single C-terminal residue rather than a dipeptide. Its role as a counter-regulator of the classical RAS axis — opposing the vasoconstrictive and pro-fibrotic actions of angiotensin II — made it an important research target in cardiovascular and renal physiology well before its role as a viral receptor was established. Recombinant ACE2 has been used extensively in substrate-profiling experiments to define the enzyme's cleavage specificity across vasoactive peptides including neurotensin, kinetensin, des-Arg bradykinin, and the apelin family. ACE2 gained broader research attention following the identification of SARS-CoV (2003) and subsequently SARS-CoV-2 (2019) as coronaviruses that engage ACE2 as their cellular entry receptor through the viral spike protein. This interaction has since been characterised structurally and biophysically in considerable detail, and recombinant ACE2 protein — particularly the glycosylated ectodomain produced in mammalian expression systems — has become a standard reagent in spike-binding assays, neutralisation controls, and entry-inhibition screens. Chandrabalan et al. (2026, Sci Rep) demonstrated that annexin A5 engages both the spike protein and ACE2 simultaneously to inhibit viral entry, illustrating the use of recombinant ACE2 as a binding partner in multi-component inhibition studies. Separately, Yokogawa et al. (2026, J Mol Biol) described allosteric targeting of the ACE2 dimer interface by a medium-sized compound that inhibits SARS-CoV-2 entry, a study dependent on well-characterised recombinant ACE2 for structural and functional validation. Beyond virology, ACE2 expression and shedding have been studied as a research target in the context of acute lung injury, heart failure, diabetes-associated vascular dysfunction, and gut amino acid absorption — the latter via ACE2's C-terminal collectrin-like domain and its role in trafficking the neutral amino acid transporter SLC6A19 to intestinal epithelial membranes. Tropism studies profiling which tissues and cell types express sufficient ACE2 to support productive viral infection rely on well-characterised antibody and recombinant protein panels for immunohistochemical and biochemical confirmation. Researchers building such panels should note that species cross-reactivity for this recombinant is validated for human; predicted cross-reactivity to mouse, rat, monkey, dog, and cat is based on sequence homology and has not been independently validated by Triple Point Biologics.

Applications

  • Carboxypeptidase activity assay using fluorogenic substrates (e.g., Mca-APK-Dnp) to measure Km and kcat
  • Inhibitor IC50 determination — small-molecule or peptide inhibitor screening against ACE2 enzymatic activity
  • SARS-CoV-2 spike RBD binding assay by SPR, BLI, or ELISA-format protein–protein interaction measurement
  • Entry-inhibition screen: competitive displacement of spike–ACE2 interaction by candidate blocking compounds or proteins
  • Antibody validation positive control — use as coating antigen or Western blot standard, paired with matched antibody SKU RP-ACE2
  • Substrate-profiling studies: cleavage of apelin peptides (apelin-13, apelin-17, apelin-36), casomorphins, and dynorphin A
  • Allosteric and dimer-interface binding studies requiring defined, glycosylated recombinant ACE2 ectodomain
  • ACE2 shedding and ADAM17/TMPRSS2 processing assays to characterise ectodomain release kinetics

References

  1. Yokogawa M et al. Allosteric targeting of the ACE2 dimer interface by a medium-sized compound inhibits SARS-CoV-2 entry. J Mol Biol. 2026. doi:10.1016/j.jmb.2026.169914 PMID: 42331085
  2. Matsui Y et al. Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells. bioRxiv. 2026. doi:10.64898/2026.06.10.731427 PMID: 42327335
  3. Jin X et al. A survey of SARS-CoV-2 tropism. Infect Dis Immun. 2025. doi:10.1097/ID9.0000000000000166 PMID: 42325371
  4. Chandrabalan A et al. Dual engagement of Spike and ACE2 by annexin A5 contributes to pleiotropic SARS-CoV-2 inhibition. Sci Rep. 2026. doi:10.1038/s41598-026-58451-9 PMID: 42323371
  5. Dinç HÖ et al. Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections. J Med Virol. 2026. doi:10.1002/jmv.71026 PMID: 42313401

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface (cleavable ectodomain)

Frequently Asked Questions

What molecular weight band should I expect for recombinant ACE-2 on SDS-PAGE or Western blot?

The recombinant ACE-2 ectodomain (residues 18–740) has a predicted molecular weight of approximately 85 kDa based on amino acid sequence alone. However, because this protein is produced in HEK293 cells, N-linked glycosylation adds substantial mass — expect a diffuse band running between 100–120 kDa under denaturing conditions. The smearing is characteristic of native-like glycosylation and is not a sign of degradation. If you require a sharper band for a loading standard, PNGase F treatment will collapse the band toward the predicted 85 kDa backbone.

Which isoform or processing form of ACE-2 is in the Triple Point Biologics recombinant — full-length or ectodomain?

This product contains the soluble ectodomain corresponding to approximately residues 18–740 of the full-length 805-amino acid human ACE-2 (UniProt Q9BYF1). The N-terminal signal peptide (residues 1–17) and the single-pass transmembrane anchor plus cytoplasmic tail (roughly residues 741–805) are absent. This is the form released naturally by ADAM17/TACE shedding and is the biochemically active construct used in the vast majority of carboxypeptidase activity and receptor-binding studies.

What substrates does recombinant ACE-2 cleave and how do I measure carboxypeptidase activity in vitro?

ACE-2 cleaves a single C-terminal amino acid from its substrates. For fluorometric activity assays, the synthetic quenched substrate Mca-APK(Dnp) (also sold as ACE-2 Fluorogenic Substrate I) is the most commonly used option, generating a signal at Ex/Em 320/405 nm. Physiological substrates include angiotensin II (→ angiotensin 1-7), angiotensin I (→ angiotensin 1-9), apelin-13, apelin-17, and dynorphin A. Run reactions in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 µM ZnCl₂ at 37°C. Include 50 µM MLN-4760 or DX600 as inhibitor controls to confirm ACE-2-specific signal.

What starting concentration of recombinant ACE-2 should I use in a carboxypeptidase activity assay?

For initial dose-response or inhibitor IC50 experiments, 1–10 nM of this recombinant ACE-2 ectodomain is a practical starting range with the Mca-APK(Dnp) substrate at 10–50 µM. At 1 nM enzyme, you should achieve a linear signal increase for at least 30–60 minutes at 37°C, which is the window needed for reliable initial-velocity measurements. If your readout is endpoint rather than kinetic, 5 nM is a reasonable fixed concentration. Avoid exceeding 25 nM in inhibitor assays, as substrate depletion artifacts become significant within the assay window.

What buffer conditions are optimal for recombinant ACE-2 enzymatic activity, and does the storage buffer inhibit activity?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — is compatible with activity assays at dilutions of 1:10 or greater; glycerol carryover below 1% final concentration does not measurably suppress ACE-2 carboxypeptidase activity. ACE-2 is a zinc metalloproteinase, so avoid EDTA or EGTA in assay buffers, as chelation of the active-site Zn²⁺ causes rapid inactivation. Supplementing the assay buffer with 10 µM ZnCl₂ is recommended when working with dilute enzyme preparations or prolonged incubations. Optimal pH is 6.5–7.5; activity drops noticeably below pH 6.

Can I use Triple Point Biologics recombinant ACE-2 as a positive control for Western blot with the RP-ACE2 matched antibody?

Yes — this is one of the primary intended uses of REC-ACE2. The matched rabbit polyclonal antibody RP-ACE2 (/anti-ace-2-rabbit-polyclonal-antibody) is raised against the ACE-2 ectodomain and has been validated by Western blot against this exact recombinant protein. Load 25–100 ng of REC-ACE2 per lane alongside your cell lysate or tissue samples. Expect a band at 100–120 kDa due to glycosylation. Because both products come from the same laboratory, there is no ambiguity about epitope coverage or cross-reactivity — the pairing is experimentally confirmed, not predicted.

How much recombinant ACE-2 should I load per lane for Western blot positive control, and what dilution of RP-ACE2 antibody works?

Load 50 ng of REC-ACE2 per lane as a starting point; this reliably produces a strong, clean band at 100–120 kDa without saturating the signal. If you are titrating antibody concentration alongside cell lysates, a 25 ng lane for REC-ACE2 keeps the positive control from overwhelming adjacent sample lanes. For RP-ACE2, a primary antibody dilution of 1:500–1:2000 in 5% BSA/TBST is typical for Western blot; we recommend starting at 1:1000. These parameters were established with this recombinant as the standard, so signal and background should be predictable.

How should I handle, dilute, and store recombinant ACE-2 to maintain enzymatic activity long-term?

REC-ACE2 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and should be stored at -20°C in single-use aliquots immediately upon receipt. Avoid repeated freeze-thaw cycles — each cycle can reduce specific activity by 10–20% for metalloproteinases. For dilutions below 10 µg/mL, use assay buffer supplemented with 0.1% BSA as a carrier to prevent adsorptive loss to tube walls. Purity is >90% by SDS-PAGE and endotoxin is <0.1 EU/µg by LAL, so the preparation is suitable for cell-based assays where endotoxin contamination would confound results.

Validation imagery coming soon

Western blot validation figures for REC-ACE2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →